Back

Do we need PCSK9 inhibitors in post-MI patients? Conclusion and take home message.

27 August 2017 (12:20 - 12:30)
Organised by:
Congress Presentation Part of: Do we need PCSK9 inhibitors in post-MI patients? Drug therapy ESC Premium Access ESC Congress 2017

About the speaker

Photo
Professor Terje Rolf Pedersen

Ulleval University Hospital, Oslo (Norway)

7 More presentations in this session

Presentation thumbnail
Opening question.
Slides Video
Presentation thumbnail
Positioning of the topic - The PCSK9 story .. so far
Professor F. Mach (Geneva, CH)
Slides Video
Presentation thumbnail
Do we need PCSK9 inhibitors in post-MI patients? PRO
Professor M. Sabatine (Boston, US)
Slides Video
Presentation thumbnail
Do we need PCSK9 inhibitors in post-MI patients? CON
Professor H. Drexel (Feldkirch, AT)
Slides Video
Presentation thumbnail
Do we need PCSK9 inhibitors in post-MI patients? Rebuttal PRO
Professor M. Sabatine (Boston, US)
Video

Access the full session

Session thumbnail
Do we need PCSK9 inhibitors in post-MI patients?

The Event

Event poster

ESC Congress 2017

27 August 2017 12:20 CET
You may be interested in
thumbnail
Webinar
LDL-C reduction postACS: strike early and strike strong
15 November 2021
thumbnail
Congress Presentation
Effect of PCSK9 inhibitors on coronary plaque: a meta-analysis and trial sequential analysis
1 September 2025
thumbnail
Congress Presentation
Cost impact of the ESC/EAS 2019 dyslipidemia guidelines recommended use of PSCK9i in very-high-risk patients with an LDL <1.8mmol/L for secondary prevention
26 August 2023
thumbnail
Webinar
Injectable therapies for cardiovascular disease: optimising their use in practice - experiences from the UK and Italy
18 March 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources